Takeda has reported positive results from its phase 3 G-HOPE-001 trial of anti-CLDN18.2 drug arcotatug tavatecan (TAK-921) in ...

The most consequential changes in cancer biology can often occur before they become visible on a scan. Yet, modern cancer ...

As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive ...

An overview of the NHS’s AI-Assisted Discharge Summarisation (AADS) project and what it takes to move AI beyond the pilot ...

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...

Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO ...

China has firmly emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could ...

In the new guidance, the agency has concluded that AI-Rad Companion Prostate MR, DeepHealth Prostate, ProstatID, Prostate ...

Roche's drugs business brought in CHF 11.47 billion (nearly $14 billion) in the three months, slightly ahead of analyst ...

Despite a string of US policy initiatives designed to curb medicine pricing under recent administrations, the annual cost of ...

Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...

Hibsago, has been approved in the US, its second major market after Japan, giving patients hope of a functional cure without ...